Anokion raises $40M series B, grabs back programs from spinout

Alongside raising $40 million in a series B round, autoimmune company Anokion said Wednesday it will acquire Kanyos Bio, a company it spun out and partnered with Astellas in 2015.

Versant Ventures, Novartis Venture Fund, Novo Ventures, select

Read the full 376 word article

How to gain access

Continue reading with a
two-week free trial.